NEW YORK, July 25, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The next generation sequencing market reached $231.7 million in 2012. The market is expected to reach $510.7 in 2013 and $7.6 billion in 2018 for a compound annual growth rate (CAGR) of 71.6%. The pre- and post-natal disease class as a segment was valued at $161.5 million in 2012. It is expected to reach $393.3 million in 2013 and nearly $2.1 billion in 2018, a CAGR of 39.4%. The cancer disease class as a segment was valued at $36.1 million in 2012. It is expected to reach $63.7 million in 2013 and nearly $2.5 billion in 2018, a CAGR of 108.3%.
STUDY GOALS AND OBJECTIVES
BCC Research's goal for this study is to provide an in-depth analysis of the clinical next generation sequencing (NGS) industry, an emerging industry with enormous market potential. The approach of analyzing the industry is taken in terms of workflow (e.g., sequencers, sequence capture, informatics) and key indications where NGS diagnostics will have market share by 2018. BCC Research examines the markets for NGS diagnostics for the years 2012, 2013 and 2018. The global NGS diagnostic markets are characterized and quantified by disease indication, test complexity, test purpose and geography. Market segments that provide exciting growth opportunities include cancer,
Copyright©2012 PR Newswire.
All rights reserved